Results 151 to 160 of about 8,133 (247)
Incretins (GLP-1 Receptor Agonists) and Polycystic Ovaries. [PDF]
Piazza MJ.
europepmc +1 more source
Recent advances in incretin biology and therapeutics: From glucose-dependent insulinotropic polypeptide reappraisal to next-generation agonists. [PDF]
Kubota S, Seino Y, Yabe D.
europepmc +1 more source
MAFLD/MASLD: Past, Present, and Future
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD), also known as nonalcoholic fatty liver disease and metabolic dysfunction‐associated fatty liver disease, affects more than 30% of the global adult population and has become one of the leading causes of cirrhosis and hepatocellular carcinoma.
Vincent Wai‐Sun Wong
wiley +1 more source
The role of gut microbiota-immune-endocrine crosstalk in the pathogenesis of osteoporosis. [PDF]
Xie X, Chen X, Wang Z, Chen Y, Li J.
europepmc +1 more source
p‐STAT3‐positive cells in metabolically relevant peripheral organs and tissues from mice administered with recombinant CNTF (0.3 mg/kg). Abstract Administration of ciliary neurotrophic factor (CNTF) reduces food intake and body weight in both humans and experimental animals, where it also ameliorates hyperglycemia, hyperinsulinemia, and dyslipidemia ...
Chiara Galli +6 more
wiley +1 more source
Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact. [PDF]
Lee AA +5 more
europepmc +1 more source
ABSTRACT Background/Aim We conducted a systematic review with network meta‐analyses (NMA) summarizing the effects and safety of lifestyle interventions containing nutrition (NUT; e.g., calorie restriction), exercise (EX; e.g., aerobic/resistance exercise) and behavior change interventions (BCI; e.g., behavioral therapy) on physical function, body ...
Gabriel Torbahn +12 more
wiley +1 more source
The therapeutic value of antidiabetic drugs in lung cancer treatment: from clinical evidence to possible mechanisms. [PDF]
Wang Q, Xu J, Liu Q, Zhou H, Hu Y.
europepmc +1 more source
Low Weight Loss Response to Incretin Analogs: A Systematic Review
ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley +1 more source
GLP-1 is associated with perfectionism in Swedish women with anorexia nervosa, independent of BMI. [PDF]
Elm S +5 more
europepmc +1 more source

